Repare Therapeutics to Participate in Two Upcoming Investor Conferences
27 Agosto 2024 - 8:05AM
Business Wire
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced that members of its senior management team will
participate at two investor conferences in September. Details for
the presentations are as follows:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat Date: Thursday, September 5, 2024 Time: 1:05 p.m.
Eastern Time Location: New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
Company Overview Date: Wednesday, September 11, 2024 Time: 9:00
a.m. Eastern Time Location: New York, NY
A live webcast of the presentations can be accessed in the
Investor section of the Company’s website at
https://ir.reparerx.com/news-and-events/events. A replay of the
webcast will be archived on the Company’s website for at least 30
days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes lunresertib (also
known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2
clinical development; camonsertib (also known as RP-3500), a
potential leading ATR inhibitor currently in Phase 1/2 clinical
development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a
preclinical Polθ ATPase inhibitor program; as well as additional,
undisclosed preclinical programs. For more information, please
visit www.reparerx.com and follow @Reparerx on X (formerly Twitter)
and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240827041601/en/
Investor Relations & Media: Robin Garner Vice
President and Head of Investor Relations Repare Therapeutics Inc.
investor@reparerx.com
Repare Therapeutics (NASDAQ:RPTX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Repare Therapeutics (NASDAQ:RPTX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024